MedPath

Intensive Education on Lipid Management

Not Applicable
Conditions
Acute Coronary Syndrome
Registration Number
NCT01925079
Lead Sponsor
Junbo Ge
Brief Summary

Among the patients with coronary heart disease, those with ACS (acute coronary syndrome) are extremely high-risk patients. Therefore, management outside hospital, especially the regular administration of drugs, is vital to prevent the recurrence of cardiovascular events. However, most patients often fail to stay on a long-term administration regimen, especially the administration of statins. According to the statistics, the average duration adhered with statin in patients with ACS is less than 3 months, use of statin at hospital discharge was only 80% and 65% in 6 month, with a very low LDL-C control rate (about 11% at 6 months), which poses a threat to the recurrence rate of cardiovascular events in patients with ACS.

It was found in previous studies that there were many factors influencing patients' compliance, in which patients' refusing to take medicine accounted for a higher proportion. It suggests that patient had not recognized the importance of long-term administration. Therefore, it is extremely important for physicians to strengthen patient education and regular follow-up visits during disease management. Moreover, the effectiveness of patient education during chronic disease management has already been proved in some studies abroad, and the interventional effect of multiple patient education process outweighs that of single approach education.

Thus, we intend to conduct a randomized and controlled study to explore the effect of multi-channel intensive patient education on LDL-C target achieving rate and statin adherence in patients with ACS in China.

Detailed Description

Not available

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
2568
Inclusion Criteria
  1. The patients admitted to the hospital with a diagnosis of ACS including those for first consulting or with recurrence. The patient was prescribed atorvastatin (Lipitor®) by physicians in hospital;
  2. The age of patient enrolled will be ≥18 years old;
  3. The patient is able to understand and complete questionnaire.
  4. The patients agree to accept follow-up visits, and willing to participate in patient education courses and sign informed consent form.
Exclusion Criteria
  1. The patient has contraindications to statins, such as active hepatic disease, patient has a history of intolerance or hypersensitivity to statins or has a history of prior rhabdomyolysis on a statin.
  2. The patient who uses other statins except Lipitor® when discharged from the hospital;
  3. Cardiac function class of the patient is class IV(NYHA);
  4. The patient has a malignant tumor;
  5. The patient has a severe arrhythmia.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Primary Outcome Measures
NameTimeMethod
LDL-C target achieving rateat Week 24 post-discharge
Secondary Outcome Measures
NameTimeMethod
the proportions of patients with statin persistenceat Week 24 post-discharge
statin complianceat Week 24 post-discharge
the relationship of LDL-C target achieving rate and statin complianceat Week 24 post-discharge
the discontinuation reason of statin therapyat Week 24 post-discharge
the difference of LDL-C control rate and statin complianceat Week 24 post-discharge

To find the difference of LDL-C control rate and statin compliance between pre-specified sub-groups: PCI or non-PCI/male or female/age (≥65) or not/ having medical insurance or not/dyslipidemia history or not /MI (myocardial infarction) or UA (unstable angina)/different risk level according to TIMI/ patients for first consulting or patients with recurrence/ have received statin in the last 3 months or not.

LDL-C target achieving rateat Week 12 post-discharge

Trial Locations

Locations (5)

Fujian Medical University Union Hospital

🇨🇳

Fuzhou, Fujian, China

The 2nd affiliated hospital of harbin medical university

🇨🇳

Harbin, Heilongjiang, China

Xi'an Jiaotong University College of Medicine

🇨🇳

Xi'an, Shanxi, China

The Luhe Teaching Hospital of the Capital Medical University

🇨🇳

Beijing, China

Shanghai Zhongshan Hospital

🇨🇳

Shanghai, China

Fujian Medical University Union Hospital
🇨🇳Fuzhou, Fujian, China
Ziliang Chen, Professor
Principal Investigator

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.